Key result
Carriage of the CYP2C19*2 (OR 1.7; 95% CI 1.0-2.6) and CYP2C9*3 (OR 2.4; 95% CI 1.0-5.5) variant alleles was significantly associated with increased risk of stent thrombosis after PCI.
Why the study?
Does the carriage of CYP2C19*2 and CYP2C9*3 alleles increase the risk of stent thrombosis in patients receiving clopidogrel and aspirin after PCI?
Population
596 patients who underwent percutaneous coronary intervention and were treated with dual antiplatelet…
Comparison
Carriage of genetic variants involved in… vs Non-carriers of the respective genetic variants.
Design
Case-control
Follow-up
1 year
Authors
Loading...
CYP2C19*2 and CYP2C9*3 alleles were associated with stent thrombosis; leaves open whether genotyping improves outcomes after PCI.
Case-Control (n=596)
Does the carriage of CYP2C19*2 and CYP2C9*3 alleles increase the risk of stent thrombosis in patients receiving clopidogrel and aspirin after PCI?
Odds Ratio: 1.7 (95% CI 1–2.6)
p-value: p=0.018
Carriage of loss-of-function alleles CYP2C19*2 and CYP2C9*3 is associated with an increased risk of stent thrombosis in patients treated with clopidogrel after PCI.
Harmsze et al. (2010) conducted a case-control in Stent thrombosis after percutaneous coronary intervention (n=596). CYP2C19*2 and CYP2C9*3 variant alleles vs. Absence of variant alleles was evaluated on Stent thrombosis (OR 1.7, 95% CI 1.0-2.6, p=0.018). Carriage of the CYP2C19*2 (OR 1.7; 95% CI 1.0-2.6) and CYP2C9*3 (OR 2.4; 95% CI 1.0-5.5) variant alleles was significantly associated with increased risk of stent thrombosis after PCI.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: